Eurosurv. Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

[tetano]

• Jesús Castilla[SUP]1,2,3[/SUP] , Óscar Lecea[SUP]4[/SUP] , Carmen Martín Salas[SUP]3,5[/SUP] , Delia Quílez[SUP]6[/SUP] , Ana Miqueleiz[SUP]3,5[/SUP] , Camino Trobajo-Sanmartín[SUP]1,2,3[/SUP] , Ana Navascués[SUP]3,5[/SUP] , Iván Martínez-Baz[SUP]1,2,3[/SUP] , Itziar Casado[SUP]1,2,3[/SUP] , Cristina Burgui[SUP]1,2,3[/SUP] , Nerea Egüés[SUP]1,2,3[/SUP] , Guillermo Ezpeleta[SUP]1[/SUP] , Carmen Ezpeleta[SUP]3,5[/SUP]

In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05–0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47–2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.33.2200619#html_fulltext